Brief: Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting Myc-Driven Non-Small Cell Lung Cancer
12/10/2022 12:23
Oct 12 (Reuters) - Omega Therapeutics Inc OMGA.O :
* OMEGA THERAPEUTICS UNVEILS NEW EPIGENOMIC CONTROLLER
DEVELOPMENT
CANDIDATE TARGETING MYC-DRIVEN NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nPn5DsfcRa
Further company coverage: OMGA.O
Recent news on Omega Liquidating
See all newsBrief: Omega Therapeutics Files For Chapter 11 Bankruptcy In U.S. - Court Filing
Brief: Omega Therapeutics Announces Entry Into New Financing Facilities To Fund Sale Process And Wind Down Of Any Remaining Co Assets
Brief: Omega Therapeutics Receives Notice Of Default Under The Loan And Security Agreement Between Company And Banc Of California
U.S. RESEARCH ROUNDUP- Applied Materials, Disney, Walmart
Brief: Flagship Pioneering Announces Appointment Of Junaid Bajwa As Senior Partner, Head Of United Kingdom, And Science Partner For Pioneering Intelligence